Kai Rejeski, MD, LMU Hospital Munich, Munich, Germany, talks on CAR T-cell associated hematotoxicity in patients treated in the real-world setting. CD19-specific CAR T-cells have revolutionized the treatment of relapsed/refractory B-cell malignancies. Yet, their clinical success is associated with unique toxicities such as prolonged cytopenias. The identification of potential biomarkers that could be detected prior to CAR T-cell therapy would help understand which patients are at risk. Dr Rejeski discusses the score his group developed, the CAR-HEMATOTOX, to model hematotoxicity and highlights its clinical applications. This interview took place during the 3rd European CAR T-cell Meeting.